Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTI164 for autism spectrum disorder in children and adolescents
ACTRN12622001398796Phase 3Completed
- Sponsor
- Fenix Innovation Group
- Start
- Feb 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Randomized NTI164 arm with Randomized placebo arm (2 arms). Primary endpoint: Change in Clinical Global Impression-Severity (CGI-S) at Week 8. Started Feb 2023; status: completed.
02
Drugs
NTI164
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12622001398796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001398796.